Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 71.1%

Neg 0% Neu 71.1% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.